Ocugen (NASDAQ:OCGN) Stock, Quote.Headers.trade-ideas

Ocugen

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

eye-5248678

News

OCGN

Ocugen shares are trading lower by 11% Thursday morning. The company announced the pricing of its public offering.

Why Ocugen (OCGN) Stock Is Falling

movers

Pre-Market Outlook

Markets

Movers

Trading Ideas

ARQT

QGEN

SEDG

VNDA

Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

xr:d:DAFjWRRL4Oc:2,j:5026988134,t:23051909

ASTS

CBRL

ERAS

TELL

TTWO

DXC Technology Issues Weak Outlook, Joins Take-Two Interactive And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

Ocugen Inc

Biotech

Health Care

Press Releases

General

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Legal

Grabar Law Office Is Investigating Claims On Behalf Of Long-Term Shareholders Of Atkore Inc. (NYSE: ATKR); Crocs, Inc. (NASDAQ: CROX); Methode Electronics, Inc. (NYSE: MEI); and Ocugen, Inc. (NASDAQ: OCGN)

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Methode Electronics, Inc. (NYSE: MEI); and Ocugen, Inc. (NASDAQ: OCGN)

Ocugen Announces Positive Opinion of EMA's Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

Earnings

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Attention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); MGP Ingredients, Inc. (NASDAQ: MGPI); and Ocugen, Inc. (NASDAQ: OCGN): Grabar Law Office Investigates Claims on Your Behalf

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

ATKR

CROX

DRVN

MGPI

MRCY

Anika Therapeutics

Annexon

Candel Therapeutics

Cidara Therapeutics

Cardiff Oncology

Cargo Therapeutics

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Design Therapeutics

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

Genfit

Gossamer Bio

Humacyte

TuHURA Biosciences

Immutep Limited - American Depositary Shares

Immutep

INmune Bio

Inventiva S.A. - American Depository Shares

Inventiva

Kodiak Sciences

Neurogene

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Prime Medicine

Regulus Therapeutics

Acelyrin

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

Y-mAbs Therapeutics

Chardan Capital

HC Wainwright & Co.

Maxim Group

Cantor Fitzgerald

Mizuho

Comments

Ocugen

Ocugen (NASDAQ:OCGN) Stock, Quote.Headers.trade-ideas

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell